|Bid||1.1900 x 70000|
|Ask||1.3300 x 70000|
|Day's Range||1.2200 - 1.2200|
|52 Week Range||1.0064 - 3.6900|
|Beta (3Y Monthly)||2.13|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Grand Prairie, Texas-based company said it had a loss of 15 cents per share. The pharmaceutical company posted revenue of $14.6 million in the period. The company's shares closed at $2.08. A year ago, ...
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies. Warning! GuruFocus has detected 1 Warning Sign with NEOS. For the last quarter Neos Therapeutics Inc reported a revenue of $15.4 million, compared with the revenue of $7.11 million during the same period a year ago.
On a per-share basis, the Grand Prairie, Texas-based company said it had a loss of 23 cents. The pharmaceutical company posted revenue of $15.4 million in the period. For the year, the company reported ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 13) Abbott Laboratories (NYSE: ABT ) Akari Therapeutics ...
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of -7.50% and -15.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Grand Prairie, Texas-based company said it had a loss of 43 cents per share. The pharmaceutical company posted revenue of $12.5 million in the period. The company's shares closed at $2.58. A year ago, ...